Mobile Site ›

Hematology and Hematopathology

Flow Cytometry Laboratory

Featured Test

Plasma Cells

Plasma Cell DNA Content and Proliferation, Bone Marrow
(Test ID: PCPRO)

Detecting plasma cell clonality through demonstrating immunoglobulin (Ig) light chain restriction (ie, the presence of either predominately kappa or predominately lambda light chains), supplemented by the plasma cell immunophenotype and DNA index, is an important element in:

  • Establishing a diagnosis of a plasma cell proliferative disorder
  • Providing prognostic information for newly diagnosed multiple myeloma and other plasma cell proliferative disorders
  • Assessing response to therapy and detecting disease relapse and progression in treated plasma cell proliferative disorder patients
  • Determining plasma cell DNA content and proliferation

Learn more...

Testing of Benign and Malignant Hematopoietic Disorders

The Flow Cytometry Laboratory offers a premium analytic and interpretative flow cytometry laboratory service in the analysis and interpretation of benign and malignant hematopoietic disorders by hematopathologists with extensive practical experience. Our instruments include the latest state-of-the-art multi-color flow cytometers. Specific areas of expertise at Mayo Clinic commonly used in the interpretation of flow cytometric studies are:

  • Chronic lymphocytic leukemia (CLL) and chronic lymphoproliferative disorders
  • Plasma cell proliferative disorders (multiple myeloma, monoclonal gammopathy of undetermined significance [MGUS])
  • Large granular lymphocytic (LGL) disorders
  • Acute leukemias
  • Malignant lymphomas (lymph node and other solid tissue)
  • Chronic myeloid malignancies

Optimal Test Utilization

Clinical information is often incomplete at the time of ordering. Our triage approach was developed for optimal utilization of resources. Collaboration with clinical colleagues at Mayo Clinic has enabled the Flow Cytometry Laboratory to develop a unique approach in utilizing resources that limits testing while still fulfilling the higest standards and avoiding unnecessary expenses to the patient:

  • Triage approach: Specimens are evaluated by specific panels (B-cell, T-cell, myeloid, plasma cell) based on the clinical history, results of the triage tube, and morphologic review of the slide.
  • Coordination with molecular and cytogenetic testing
  • Direct phone communication with the ordering physician to ensure relevant testing
  • Validation of testing algorithms

Expert Consultants

Our staff of board-certified hematopathologists interprets results and is available for questions regarding testing, clinical utilization, and differential diagnosis. Our hematopathologists have diagnostic expertise honed by collaboration with the large clinical hematology practice at Mayo Clinic and are national and international experts on both myeloid and lymphoid disorders.


Key